heparin-induced thrombocytopenia , HIT (Abkürzung)

Smaller risk of heparin-induced thrombocytopenia, a potential side effect of heparin.

Heparin-induced thrombocytopenia in the critical-care setting: diagnosis and management.

Heparin-induced thrombocytopenia, a complication of heparin used post surgery.

Glucosamine sulfate does not crossreact with the antibodies of patients with heparin-induced thrombocytopenia.

A serious side-effect of heparin is heparin-induced thrombocytopenia (HIT).

It is also used as a heparinoid substitute in heparin-induced thrombocytopenia (HIT) which may otherwise cause paradoxical thrombosis.

Still, LMWHs are much less likely to cause heparin-induced thrombocytopenia than unfractionated heparin.

Heparin-induced thrombocytopenia (HIT) is due to an immune system reaction against the anticoagulant drug heparin (or its derivatives).

Lepirudin may be used as an anticoagulant when heparins (unfractionated or low-molecular-weight) are contraindicated because of heparin-induced thrombocytopenia.

Drug-induced thrombocytopenic purpura (for example heparin-induced thrombocytopenia (HIT))

Venous limb gangrene may be caused by heparin-induced thrombocytopenia and thrombosis (HITT).

Heparin-induced thrombocytopenia (HIT) is increasingly common among patients receiving ECMO.

Heparin-induced thrombocytopenia (HIT)

Heparin can also cause a prothrombotic condition, heparin-induced thrombocytopenia (an antibody-mediated decrease in platelet levels), which increases the risk for thrombosis.

Ancrod has been shown to be useful for maintaining anticoagulation in the presence of Heparin-induced thrombocytopenia (HIT) and thrombosis.

In general, low platelet counts increase bleeding risks; however there are exceptions (such as immune-mediated heparin-induced thrombocytopenia or paroxysmal nocturnal hemoglobinuria).

The heparin:PF4 complex is the antigen in heparin-induced thrombocytopenia, an idiosyncratic autoimmune reaction to the administration of the anticoagulant heparin.

Major side effects of tinzaparin are osteoporosis (occurring in up to 1% of cases), thrombocytopenia (heparin-induced thrombocytopenia), haemorrhage, hair loss and drug allergy.

It should also be avoided in those with heparin-induced thrombocytopenia (HIT) or disseminated intravascular coagulation (DIC).

With LMWH and fondaparinux, there is a reduced risk of osteoporosis and heparin-induced thrombocytopenia (HIT).

Some patients can have certain bad reactions to heparin (heparin-induced thrombocytopenia-HIT or heparin-induced thrombocytopenia and thrombosis-HITT).

Lepirudin is approved for the treatment of heparin-induced thrombocytopenia (HIT) in the USA, Canada, Europe and Australia.

Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant.

Older terminology distinguishes between two forms of heparin-induced thrombocytopenia: type 1 (mild, non-immune mediated and self-limiting fall in platelet count) and type 2, the form described above.

One potential advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia (HIT) is substantially lower.